Summary of Key Points Core Viewpoint - Several shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership dynamics within the market [1]. Group 1: Shareholder Reductions - Hongbo New Materials' shareholder, Xinyu Baolong, intends to reduce its stake by 3% [1]. - Dayilong's shareholder, Lefeng Investment, has reduced its stake by 3% [1]. - Ningbo Zhongbai's Zhang Jiangbo plans to reduce his stake by 1% [1]. - Founder Securities reports that China Cinda plans to reduce its stake by 1% within three months [1]. - Liqun Co., Ltd.'s director, Hu Peifeng, intends to reduce his stake by 0.08% [1]. - Suli Co., Ltd.'s Guosheng Investment plans to reduce its stake by 0.4816% [1]. - Jinzhen Co., Ltd.'s Zhao Jian and Xu Minbo have reduced their stakes by 0.98% and 0.11%, respectively [1]. - Shenkong Technology's Wang Huan and Zhou Baocong plan to reduce their stakes by up to 0.0263% and 0.0210% within three months [1]. - Huaxi Biological's shareholder, Guoshou Chengda, plans to reduce its stake by no more than 2% [1]. - Xuanta Pharmaceutical's Qihe Venture has reduced its stake by 0.7098% [1]. - Desheng Technology's actual controller, Guo Xiaobin, has reduced his stake by 0.51% [1]. - Liren Technology's Liren Investment has reduced its stake by 0.0779% [1]. Group 2: Shareholder Increases - Zhongju Gaoxin's Li Ruxiong has increased his stake by 0.0129% [1].

上海复旦张江生物医药股份有限公司 2025 年第一次临时股东大会 会议资料 二〇二五年十一月 | 会议须知 | 1 | | --- | --- | | 会议议程 | 3 | | 会议议案 | 5 | | 议案 1：《关于变更部分募集资金投资项目的议案》 | 5 | | 议案 2：《关于修订<公司章程>及取消监事会的议案》 | 17 | | 议案 3：《关于修订<股东大会议事规则>的议案》 | 19 | | 议案 4：《关于修订<董事会议事规则>的议案》 | 20 | | 附件一：《公司章程》修订对照表 | 21 | | 附件二：《股东大会议事规则》修订对照表 | 80 | | 附件三：《董事会议事规则》修订对照表 | 96 | 上海复旦张江生物医药股份有限公司 2025 年第一次临时股东大会 会议须知 为了维护全体股东的合法权益、保障股东依法行使股东权利，确保股东大会 的正常秩序和议事效率，根据《中华人民共和国公司法》《中华人民共和国证券 法》、中国证监会《上市公司股东会规则》以及《上海复旦张江生物医药股份有 限公司章程》及《上海复旦张江生物医药股份有限公司股东大会议事规则》等有 关规定，特制订本须知。 一、 ...

一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 证券代码：688505 证券简称：复旦张江 公告编号：临 2025-037 上海复旦张江生物医药股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 召开日期时间：2025 年 11 月 26 日 13 点 00 分 召开地点：上海市浦东新区张江高科技园区蔡伦路 308 号 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 26 日 至2025 年 11 月 26 日 股东大会召开日期：2025年11月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票 ...

截至本公告披露日，上海复旦张江生物医药股份有限公司（以下简称"公司" 或"复旦张江"）股东杨宗孟先生持有公司股份 64,009,773 股，占公司总股本的 6.18%。杨宗孟先生所持有的公司股份来源为公司首次公开发行前取得的股份， 该部分股份已于 2023 年 6 月 19 日起全部解除限售并上市流通。 减持计划的主要内容 证券代码：688505 证券简称：复旦张江 公告编号：临 2025-038 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 公司于近日收到杨宗孟先生发来的《关于减持复旦张江股份计划的告知函》， 因自身资金需求，杨宗孟先生计划自本公告披露之日起 15 个交易日后的 3 个月 内通过集中竞价的方式减持公司股份不超过 10,365,721 股，拟减持比例不超过公 司总股本的 1.00%。 根据杨宗孟先生于《复旦张江首次公开发行股票并在科创板上市招股说明书》 作出的承诺："本人减持所持有公 ...

Core Viewpoint - Fudan Zhangjiang (688505.SH) announced that Mr. Yang Zongmeng plans to reduce his shareholding in the company due to personal funding needs, intending to sell up to 10.3657 million shares, which represents no more than 1% of the company's total share capital [1] Summary by Category - **Shareholding Reduction Plan** - Mr. Yang Zongmeng intends to reduce his holdings through centralized bidding within three months after a 15 trading day notice period [1] - The maximum number of shares to be sold is 10.3657 million [1] - The planned reduction will not exceed 1% of the total share capital of the company [1]

Core Viewpoint - Fudan Zhangjiang (688505.SH) announced that Mr. Yang Zongmeng plans to reduce his shareholding in the company due to personal funding needs, intending to sell up to 10.3657 million shares, which represents no more than 1% of the company's total share capital [1] Summary by Relevant Sections - Shareholding Reduction Plan - Mr. Yang Zongmeng intends to reduce his holdings through centralized bidding within three months after a 15 trading day period from the announcement date [1] - The maximum number of shares to be sold is 10.3657 million [1] - The planned reduction will not exceed 1% of the total share capital of the company [1]

Core Viewpoint - Fudan Zhangjiang announced that shareholder Yang Zongmeng, holding 64.0098 million shares (6.18% of total shares), plans to reduce his holdings by up to 10.3657 million shares (not exceeding 1.00% of total shares) within three months starting from November 26, 2025, to February 25, 2026, at a price not lower than 8.64 yuan per share after adjustment for ex-rights and ex-dividends [1] Summary by Sections - Shareholder Information - Yang Zongmeng holds 64.0098 million shares, representing 6.18% of the total shares [1] - Reduction Plan - The planned reduction is up to 10.3657 million shares, which is a maximum of 1.00% of total shares [1] - The reduction period is set from November 26, 2025, to February 25, 2026 [1] - Pricing Details - The minimum selling price for the reduced shares is set at 8.64 yuan per share, adjusted for ex-rights and ex-dividends [1]

Core Viewpoint - Fudan Zhangjiang (01349) announced that shareholder Yang Zongmeng plans to reduce his stake in the company due to personal funding needs, intending to sell up to 10,365,721 shares, which represents a maximum of 1.00% of the company's total share capital [1] Summary by Relevant Sections - Shareholder Action - Yang Zongmeng has issued a notice regarding his plan to reduce his holdings in Fudan Zhangjiang [1] - The reduction will occur through centralized bidding within three months after a 15 trading day period following the announcement [1] - Share Reduction Details - The maximum number of shares to be sold is 10,365,721 [1] - This reduction accounts for no more than 1.00% of the total share capital of the company [1]

Group 1 - The core point of the article is that Fudan Zhangjiang (01349) has received a notice from shareholder Yang Zongmeng regarding a plan to reduce his shareholding in the company due to personal funding needs [1] - Yang Zongmeng plans to reduce his holdings by no more than 10,365,721 shares, which represents up to 1.00% of the company's total share capital [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃上海復旦張江生物醫藥股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司關 於持股 5%以上股東減持股份計劃公告》，僅供參閱。該文件及其披露內容乃根據中國 法律法規及境內相關監管要求而編制及刊發。 承董事會命 趙大君 主 席 於本公告刊發日期，董事會包括以下人士： 趙大君先生（執行董事） 中國·上海 二零二五年十一月四日 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 *僅供識別 薛 燕女士（執行董事） 沈 波先生（非執行董事） 余曉陽女士（非執行董事） 王宏廣先 ...